Molecular Partners AG
MOLN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.06 | -0.05 | 0.10 |
| FCF Yield | -9.03% | -11.65% | -13.86% | -9.09% |
| EV / EBITDA | -2.61 | -1.67 | -2.91 | -8.01 |
| Quality | ||||
| ROIC | -11.85% | -15.38% | -12.10% | -9.93% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.64 | 1.02 | 1.17 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -56.88% | -51.72% | -70.29% |
| Free Cash Flow Growth | 24.55% | 24.71% | -31.47% | 1.54% |
| Safety | ||||
| Net Debt / EBITDA | 7.15 | 4.04 | 4.89 | 5.77 |
| Interest Coverage | -4,015.00 | -4,329.25 | -3,228.40 | -2,465.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -22.94 | -16.57 | -18.09 | -6.47 |